EN PL
PRACA ORYGINALNA
Spironolactone (an adjuvant therapy) in rheumatoid arthritis: a case control study
 
Więcej
Ukryj
 
Data nadesłania: 08-02-2018
 
 
Data ostatniej rewizji: 03-03-2018
 
 
Data akceptacji: 28-03-2018
 
 
Data publikacji online: 09-05-2018
 
 
Data publikacji: 30-04-2018
 
 
Reumatologia 2018;56(2):87-91
 
SŁOWA KLUCZOWE
DZIEDZINY
STRESZCZENIE
Objectives:
Disease-modifying anti-rheumatic drugs (DMARDs) are conventionally used in rheumatoid arthritis (RA). The role of spironolactone as add on therapy to DMARDs in RA patients was evaluated.

Material and methods:
A total of 100 patients with rheumatoid arthritis diagnosed as per 1987 criteria having evidence of active disease despite ongoing DMARD therapy were enrolled in this study. Patients were assigned randomly to two groups. Group I (n = 50) patients were treated with 50 mg/day of spironolactone along with their maintenance DMARD and NSAID therapy. Group II (n = 50) patients continued their maintenance DMARD therapy without spironolactone. Disease activity was assessed using the Disease Activity Score-28 (DAS28) and the Clinical Disease Activity Index (CDAI) in each patient of each group was evaluated monthly for the next three months.

Results:
All patients completed the study. Mean age of group I was 46.44 ±11.67 and of group II 44.52 ±11.82. DAS28 assessed in time according to the schedule was for group I 6.78 ±0.74, 5.34 ±0.74, 3.98 ±0.7, 3.00 ±0.75, while in group II it was 6.61 ±0.82, 5.49 ±0.90, 4.58 ±0.81, 3.55 ±0.93 at baseline, 4, 8, and 12 weeks respectively. CDAI in group I was 41.68 ±11.14, 24.36 ±8.13, 12.34 ±5.73, 6.42 ±4.4 and in group II 37.84 ±11.12, 24.54 ±9.4, 16.38 ±6.81, 9.62 ±6.1 at baseline, 4, 8, and 12 weeks respectively. Group I showed significant improvement in disease activity in the form of tender joint count (p = 0.001), swollen joint count (p = 0.023), patient global assessment (p = 0.001), physician global health (p = 0.001), DAS28 (p < 0.001) and CDAI (p = 0.001) but other parameters showed non-significant improvement compared to group II. No serious adverse events were observed in either group during the course of the study.

Conclusions:
Spironolactone as an adjuvant therapy can improve the effect of conventional DMARD treatment of patients with RA.

 
REFERENCJE (22)
1.
Jurgen B. Methotrexate: optimizing the efficacy in rheumatoid arthritis. Therap Adv Musculoskelet Dis 2011; 3: 151-158.
 
2.
Jurgens JWG, Jacobs J, Bijlsma WJ. The use of conventional disease modifying antirheumatic drug in established RA. Best Pract Res Clin Rheumatol 2011; 23: 288-292.
 
3.
American College of Rheumatology: Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 328-346.
 
4.
Luukkainen R, Kajander A, Isomaki H. Effect of gold on progression of erosion in rheumatoid arthritis. Better result with early treatment. Scand J Rheumatol 1977; 6: 189-192.
 
5.
Fries JF. Re-evaluating the therapeutic approach to rheumatoid arthritis: the “saw tooth” strategy. J Rheumatol 1990; 22: 12-15.
 
6.
Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease modifying anti rheumatic drug and biological agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 6645: 625-639.
 
7.
Cutolo M, Balleari E, Giusti M, et al. Androgen replacement therapy in male patients with rheumatoid arthritis. Arthritis Rheum 1991; 34: 1-5.
 
8.
Helmy M, Shohayeb M, Helmy MH, et al. Antioxidants as adjuvant therapy in rheumatoid disease. A preliminary study. Arzneimittelforschunq 2001; 51: 293-298.
 
9.
Bahadori B, Uitz E, Thonofer R, et al. Omega-3 fatty acid infusions as adjuvant therapy in rheumatoid arthritis. J Parenter Enteral Nutr 2010; 34: 151-155.
 
10.
McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid arthritis (TARA): double blind, randomised placebo controlled trial. Lancet 2004; 363: 2015-2021.
 
11.
Komarova E, Rebrov B. Effectiveness of spironolactone in complex therapy of rheumatoid arthritis. Eur Med Health Pharm J 2014; 7: 11-13.
 
12.
Bendtzen K, Hansen PR, Rieneck K. Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis. Clin Exp Immunol 2003; 134: 151-158.
 
13.
Syngle A, Vohra K, Kaur L, et al. Effect of spironolactone on endo-thelial dysfunction in rheumatoid arthritis. Scand J Rheumatol 2009; 38: 15-22.
 
14.
Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodeling. The role of aldosterone, J Mol Cell Cardiol 2002; 34: 1577-1584.
 
15.
Sugiyama T, Yashimoto T, Hirono Y, et al. Aldosterone increases osteopontin gene expression in rat endothelial cells. Biochem Biophys Res Commun 2005; 336: 163-167.
 
16.
Marjonne CW, Creemers, Leo BA. Rheumatoid Arthritis. In: Oxford text book of rheumatology, Isenberg DA, Maddison PJ, Woo P, et al. (eds.). 3rd ed. Oxford University Press, New York 2008: 697-710.
 
17.
Bergholm R, Leirisalo-Repo M, Vehkavaara S. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002; 22: 1637-1641.
 
18.
Klimiuk PA, Sierakowski, Latosiewicz R, et al. Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis 2002; 61: 804-809.
 
19.
Rombouts K, Wielart A, Hellemans K, et al. Influence of aldosterone on collagen synthesis and proliferation of rat cardiac fibroblasts. Br J Pharmacol 2001; 134: 224-232.
 
20.
Malemud CJ. Growth hormone, VEGF and FGF: involvement in rheumatoid arthritis. Clin Chim Acta 2007; 375: 10-19.
 
21.
Huber LC, Distler O, Tarner I, et al. Synovial fibroblasts: Key players in rheumatoid arthritis. Rheumatology 2006; 45: 669-675.
 
22.
Spironolactone and Autoimmune disorder – from FDA reports. Accessed at: https://www.ehealthme.com/ds/s....
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top